Clinical Trial Update: Selinexor Treatment of Advanced Relapsed/Refractory Squamous Cell Carcinomas [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for selinexor in advanced relapsed/refractory squamous cell carcinomas; the study is terminated with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Squamous Cell Carcinoma

Drugs mentioned

• Selinexor (selinexor)

Snippet

Sponsor: Karyopharm Therapeutics Inc | Conditions: Squamous Cell Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2020-12-07